Skip to content
Open access

26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL

Sep 2026 · Dermatology Reports · Vol 18 · 0 citations · 2 references

TL;DR

This study evaluated efficacy and safety of ixekizumab and tirzepatide (IXE+TZP) compared to ixekizumab (IXE) in adults with active PsA and overweight (BMI>27-BMI>27-).

Abstract

Background. Overweight and obesity occurs in 72-82%[1,2] of patients with psoriatic arthritis (PsA) and is associated with worse clinical outcomes and increased comorbidities[3]. We evaluated efficacy and safety of ixekizumab and tirzepatide (IXE+TZP) compared to ixekizumab (IXE) in adults with active PsA and overweight (BMI>27-

Read PDF

Similar papers

Open access Sep 2026

24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL

This trial evaluated efficacy and safety of ixekizumab (IXE) with or without tirzepatide (TZP) with or without tirzepatide (TZP) in participants with psoriasis and overweight or obesity.

Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica · 0 citations
Open access Sep 2026

12 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS

Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin condition impacting 15—20% of children globally, with limited treatment options. Lebrikizumab (LEB) inhibits interleukin (IL)-13, a key driver of AD, and is approved for patients (pts) ≥12 years (y), ≥40kg with moderate-to-severe (mod-sev) AD inadeq...

Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica · 0 citations
Open access Oct 2026

Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies.

OBJECTIVES To evaluate the long-term efficacy of bimekizumab in patients with psoriatic arthritis (PsA) across the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains, PsA-related conditions, and comorbidities. METHODS Post hoc analysis of pooled data from BE OPTIMAL (NCT03895203;...

A. Deodhar, Alice B. Gottlieb, J. Merola et al. · 0 citations
Open access 2026

Retrospective observational study of the effectiveness of risankizumab and ixekizumab in patients with plaque psoriasis in real-world clinical practice

Risankizumab (anti-IL-23) and ixekizumab (anti-IL-17A) are biologic therapies for plaque psoriasis of proven efficacy in randomized clinical trials, while real-world evidence remains limited. This retrospective observational study aimed to evaluate and compare the effectiveness of these therapies during the first year...

M. Jeremić, D. Tiodorović, A. Catić-Đorđević · 0 citations
Case report Open access Sep 2026

Dual-Targeted Therapy With Upadacitinib and Ustekinumab in Pediatric Refractory Perianal Crohn's Disease

ABSTRACT Perianal Crohn’s disease (pCD) is a challenging manifestation of CD. We present the case of a 17-year-old adolescent girl with severe, refractory pCD, complicated by a rectovaginal fistula, who failed multiple lines of therapy and required a temporary ileostomy. While on upadacitinib (UPA) monotherapy, she exp...

Neha Sathe, M. Kline, Amelia Kellar et al. · 0 citations
Open access Nov 2026

The Clinical Factors Related to the Efficacy of Ozoralizumab in Patients with Rheumatoid Arthritis

Background/Objectives: Ozoralizumab, a tumor necrosis factor (TNF) blocker, was launched in Japan in 2022. However, there is no evidence to determine whether this biological agent is the best choice for patients with rheumatoid arthritis (RA). To investigate the clinical factors related to the efficacy of ozoralizumab,...

K. Kanbe, A. Kubota · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.